Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEden Regulatory News (EDEN)

Share Price Information for Eden (EDEN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.25
Bid: 4.00
Ask: 4.50
Change: 0.00 (0.00%)
Spread: 0.50 (12.50%)
Open: 4.25
High: 4.25
Low: 4.25
Prev. Close: 4.25
EDEN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of Retail Offer

2 Aug 2023 15:22

RNS Number : 1088I
Eden Research plc
02 August 2023
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, TO US PERSONS OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA ("SOUTH AFRICA") OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF EU REGULATION 596/2014 WHICH FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE WITHIN THE PUBLIC DOMAIN.

 

 

2 August 2023

 

Eden Research plc

("Eden", the "Group" or the "Company")

 

Result of Retail Offer

 

Further to the announcement dated 28 July 2023, Eden Research plc (AIM: EDEN), the AIM-quoted company that develops and supplies breakthrough biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries, is pleased to announce that, following the closing of the Retail Offer on the BookBuild Platform on 2 August 2023, 6,090,070 Ordinary Shares will be issued at a price of 6.5 pence per Retail Offer Share in connection with the Retail Offer.

 

Consequently, 13,945,076 Firm Placing Shares, 2,978,001 Firm Subscription Shares, and 6,090,070 Retail Offer Shares, resulting in a total of 23,013,147 new Ordinary Shares, will be issued in relation to the Placing, Subscription and Retail Offer, raising total gross proceeds of £1.5 million.

 

Application has been made for the Placing Shares, Subscription Shares, and Retail Offer Shares to be admitted to trading on AIM ("Admission"). Admission is expected to take place at 8.00 a.m. on 3 August 2023.

 

Following the Admission, the total number of Ordinary Shares in the capital of the Company in issue will be 404,121,754 with each Ordinary Share carrying the right to one vote. There are no Ordinary Shares held in treasury and therefore the total number of voting rights in the company is expected to be 404,121,754. The above figure may be used by Shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure, Guidance and Transparency Rules.

 

Capitalised terms used in this announcement have the meaning given to them in the placing and retail offer announcement dated 28 July 2023, unless otherwise defined in this announcement.

 

Further information on the Company can be found on its website at: https://www.edenresearch.com/ 

This announcement should be read in its entirety. In particular, the information in the "Important Notices" section of the announcement should be read and understood.

For further information, please contact:

Eden Research plc

Sean Smith

Alex Abrey

 

+44 (0) 1285 359 555

 

Cenkos Securities Nominated Adviser and Broker

Giles Balleny

Max Gould

 

 

+44 (0) 207 397 8900

 

BookBuild

Paul Brotherhood/Marc Downes

support@bookbuild.live

 

Important Notices

This announcement and the information contained herein is not for release, publication or distribution, directly or indirectly, in whole or in part, in or into or from the United States (including its territories and possessions, any state of the United States and the District of Columbia (the "United States" or "US")), Australia, Canada, Japan, the Republic of South Africa, any member state of the EEA or any other jurisdiction where to do so might constitute a violation of the relevant laws or regulations of such jurisdiction.

The Retail Offer Shares have not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act") or under the applicable state securities laws of the United States and may not be offered or sold directly or indirectly in or into the United States or to or for the account or benefit of any US person (within the meaning of Regulation S under the US Securities Act) (a "US Person"). No public offering of the Retail Offer Shares is being made in the United States. The Retail Offer Shares are being offered and sold outside the United States in "offshore transactions", as defined in, and in compliance with, Regulation S under the US Securities Act. In addition, the Company has not been, and will not be, registered under the US Investment Company Act of 1940, as amended.

This announcement does not constitute an offer to sell or issue or a solicitation of an offer to buy or subscribe for Retail Offer Shares in the United States, Australia, Canada, New Zealand, Japan, South Africa, any member state of the EEA or any other jurisdiction in which such offer or solicitation is or may be unlawful. No public offer of the securities referred to herein is being made in any such jurisdiction.

The distribution of this announcement may be restricted by law in certain jurisdictions and persons into whose possession any document or other information referred to herein comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

Cenkos Securities plc ("Cenkos") which is authorised and regulated in the United Kingdom by the Financial Conduct Authority and is a member of the London Stock Exchange, is acting exclusively for the Company and for no-one else and will not regard any other person (whether or not a recipient of this announcement) as its client in relation to the Retail Offer and Admission and will not be responsible to anyone other than the Company for providing the protections afforded to its clients, nor for providing advice in connection with the Retail Offer, Admission and the other arrangements referred to in this announcement.

The value of Ordinary Shares and the income from them is not guaranteed and can fall as well as rise due to stock market and currency movements. When you sell your investment, you may get back less than you originally invested. Figures refer to past performance and past performance is not a reliable indicator of future results. Returns may increase or decrease as a result of currency fluctuations.

Certain statements in this announcement are forward-looking statements which are based on the Company's expectations, intentions and projections regarding its future performance, anticipated events or trends and other matters that are not historical facts. These forward-looking statements, which may use words such as "aim", "anticipate", "believe", "intend", "estimate", "expect" and words of similar meaning, include all matters that are not historical facts. These forward-looking statements involve risks, assumptions and uncertainties that could cause the actual results of operations, financial condition, liquidity and dividend policy and the development of the industries in which the Company's businesses operate to differ materially from the impression created by the forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Given those risks and uncertainties, prospective investors are cautioned not to place undue reliance on forward-looking statements.

These forward-looking statements speak only as at the date of this announcement and cannot be relied upon as a guide to future performance. The Company and Cenkos expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein to reflect actual results or any change in the assumptions, conditions or circumstances on which any such statements are based unless required to do so by the Financial Conduct Authority, the London Stock Exchange or applicable law.

The information in this announcement is for background purposes only and does not purport to be full or complete. None of Cenkos or any of its affiliates, accepts any responsibility or liability whatsoever for, or makes any representation or warranty, express or implied, as to this announcement, including the truth, accuracy or completeness of the information in this announcement (or whether any information has been omitted from the announcement) or any other information relating to the Company or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of the announcement or its contents or otherwise arising in connection therewith. Cenkos and its affiliates, accordingly disclaim all and any liability whether arising in tort, contract or otherwise which they might otherwise be found to have in respect of this announcement or its contents or otherwise arising in connection therewith.

Any indication in this announcement of the price at which the Ordinary Share have been bought or sold in the past cannot be relied upon as a guide to future performance. Persons needing advice should consult an independent financial adviser. No statement in this announcement is intended to be a profit forecast and no statement in this announcement should be interpreted to mean that earnings or target dividend per share of the Company for the current or future financial years would necessarily match or exceed the historical published earnings or dividends per share of the Company.

Neither the content of the Company's website (or any other website) nor the content of any website accessible from hyperlinks on the Company's website (or any other website) is incorporated into or forms part of this announcement. The Retail Offer Shares to be issued or sold pursuant to the Retail Offer will not be admitted to trading on any stock exchange other than the London Stock Exchange.

UK Product Governance Requirements

Solely for the purposes of the product governance requirements of Chapter 3 of the FCA Handbook Product Intervention and Product Governance Sourcebook (the "UK MiFIR Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacture" (for the purposes of the UK MiFIR Product Governance Requirements) may otherwise have with respect thereto, the Retail Offer Shares have been subject to a product approval process, which has determined that the Retail Offer Shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in paragraphs 3.5 and 3.6 of COBS; and (ii) eligible for distribution through all permitted distribution channels (the "Target Market Assessment"). Notwithstanding the Target Market Assessment, distributors should note that: the price of the Retail Offer Shares may decline and investors could lose all or part of their investment; the Retail Offer Shares offer no guaranteed income and no capital protection; and an investment in the Retail Offer Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to any contractual, legal or regulatory selling restrictions in relation to the Retail Offer.

For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of Chapters 9A or 10A respectively of COBS; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Retail Offer Shares. Each distributor is responsible for undertaking its own target market assessment in respect of the Retail Offer Shares and determining appropriate distribution channels.

EU Product Governance Requirements

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the Retail Offer Shares have been subject to a product approval process, which has determined that the Retail Offer Shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "EU Target Market Assessment"). Notwithstanding the EU Target Market Assessment, distributors should note that: the price of the Retail Offer Shares may decline and investors could lose all or part of their investment; the Retail Offer Shares offer no guaranteed income and no capital protection; and an investment in the Retail Offer Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The EU Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Retail Offer.

For the avoidance of doubt, the EU Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase or take any other action whatsoever with respect to the Retail Offer Shares.

Each distributor is responsible for undertaking its own target market assessment in respect of the Retail Offer Shares and determining appropriate distribution channels.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROIEALPAEAFDEFA
Date   Source Headline
31st Jan 20247:00 amRNSBoard Change
22nd Jan 20247:00 amRNSTrading Update
19th Jan 20243:00 pmRNSHolding(s) in Company
9th Jan 20247:01 amRNSMevalone Approval in the State of California
18th Dec 20237:00 amRNSEcovelexâ„¢2023 Approval in Italy
28th Nov 20237:00 amRNSSmall Cap Virtual Investor Conference
1st Nov 20237:00 amRNSChange of Nominated Adviser and Broker
9th Oct 20234:44 pmRNSHolding(s) in Company
9th Oct 20234:39 pmRNSHolding(s) in Company
9th Oct 202312:46 pmRNSHolding(s) in Company
5th Oct 20237:00 amRNSCompletion of Conditional Placing
29th Sep 20237:01 amRNSHalf Yearly Report
29th Sep 20237:00 amRNSCapital Raising Update
31st Aug 20236:25 pmRNSGrant of Awards under Long-Term Incentive Plan
17th Aug 20239:27 amRNSResult of GM and Capital Raising update
16th Aug 20237:00 amRNSFirst Order For Ecovelex
2nd Aug 20233:22 pmRNSResult of Retail Offer
28th Jul 20235:00 pmRNSRetail Offer
28th Jul 20235:00 pmRNSPlacing and Retail Offer
3rd Jul 20237:00 amRNSRegulatory Application for Ecovelex in the UK
30th Jun 20239:17 amRNSResult of AGM
29th Jun 20237:00 amRNSAGM Statement
15th Jun 20237:00 amRNSAppointment of New Product Distributor – Colombia
9th Jun 20234:29 pmRNSHolding(s) in Company
7th Jun 20237:00 amRNSPublication of Annual Report and Notice of AGM
5th Jun 20234:47 pmRNSHolding(s) in Company
30th May 20237:00 amRNSEden and Corteva seek to bring Ecovelex to market
17th May 20237:00 amRNSExercise of Options
15th May 20237:00 amRNSMevalone authorisation in New Zealand
12th May 20237:00 amRNSRegulatory approvals in California and Florida
5th May 20237:00 amRNSPreliminary results for the year ended 31 Dec 2022
17th Apr 20237:00 amRNSRegulatory authorisation for Mevalone in Poland
23rd Mar 20237:00 amRNSUS State Regulatory Approvals Update
30th Jan 20237:00 amRNSFirst Mevalone authorisation for domestic use
10th Jan 20237:00 amRNSTrading Update
15th Dec 20222:01 pmEQSEden Research signs new Mevalone distribution deal
15th Dec 20227:00 amRNSDistribution Agreement for Mevalone in France
30th Nov 20227:00 amRNSOrganic Certification in Greece
24th Oct 202212:00 pmRNSAIM Rule 17 Notification
3rd Oct 20224:39 pmRNSHolding(s) in Company
30th Sep 20227:00 amRNSEden Half Yearly Report
28th Sep 20228:46 amRNSAppointment of Auditor
27th Sep 20225:08 pmEQSEden granted US EPA regulatory approval
26th Sep 20227:00 amRNSEden granted US EPA regulatory approval
2nd Sep 20227:00 amRNSAppointment of Non-Executive Director
22nd Aug 20227:00 amRNSTrading Update
7th Jul 20227:00 amRNSExercise of Options
29th Jun 202212:18 pmRNSResult of AGM
29th Jun 20227:00 amRNSAGM Statement
8th Jun 20227:12 amRNSNotice of AGM & Publication of Annual Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.